Reimbursement Series: Anchors Affordable Breakthroughs – AIFA and TLV Expand European Coverage
Sweden expands reimbursement decisions driving biotech access and patient impact.
Sweden expands reimbursement decisions driving biotech access and patient impact.
Poland’s Ministry of Health has announced its largest-ever reimbursement list update
Global market access shifts: HTA speed, UK pricing, digital disruption.
NICE deems donanemab and lecanemab not cost-effective, blocks NHS coverage for Alzheimer’s drugs.
Top biopharma deals, FDA approvals, and market access news from the past week.
JP Morgan Week featured notable developments in drugs, devices, diagnostics, and digital health. Johnson & Johnson paid $14.6 billion for Intra-Cellular Therapies, bolstering its neuroscience portfolio with CAPLYTA® and a strong mental health pipeline. Eli Lilly invested $2.5 billion in Scorpion Therapeutics’ PI3Kα inhibitor for hormone-positive breast cancer, while Bausch + Lomb expanded ophthalmology with … Read more